TICKERNERD
Menu
AVLNHealthcare · Biotechnology

AVLN Stock Forecast: Avalyn Pharma, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$27
+8.52% on the day

The 5 Wall Street analysts covering Avalyn Pharma, Inc. hold a median 12-month price target of $60 — +120.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 22 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
1/ 100
Median analyst target
$60
Analysts covering
5
Revenue$0.0
Operating income−$31.3M
Net income−$28.9M
Free cash flow−$26.3M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+10.6%
1M
−16.0%
From high
−30.6%
From low
+16.8%
$23
$39
Range since 30 Apr 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

AVLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Avalyn Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
1/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
41
Revisions
26
Momentum
16
Value
15
Accruals
8
Growth
8
Issuance
7
Quality
5
Volatility
3

Size (41): Smaller than most of the companies we track.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVLN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 30 Apr 2026Adjusted close, US dollars
$20$30$40$50$60$70$80May 26Jun 26Jul 26Aug 26Sep 26Oct 26AVLNHigh $80Median $60Low $52

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $52Median $60High $80

The green dot is the last close — the median target sits +120.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Oct 2026Raymond JamesInitiatesOutperform—
2 Oct 2026Raymond JamesInitiatesOutperform$60
13 Aug 2026Morgan StanleyMaintainsOverweight$53 → $57
13 Aug 2026Morgan StanleyMaintainsOverweight—
26 May 2026Evercore ISI GroupInitiatesOutperform—
26 May 2026Evercore ISI GroupInitiatesOutperform$51
26 May 2026GuggenheimInitiatesBuy$80
26 May 2026GuggenheimInitiatesBuy—
26 May 2026Morgan StanleyInitiatesOverweight—
26 May 2026Morgan StanleyInitiatesOverweight$53

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AVLN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

AVLN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

AVLN vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130May 26Jun 26Jul 26Aug 26Sep 26Oct 26AVLNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Avalyn Pharma, Inc. (AVLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.4×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
3.0×

Cheaper than 30% of US stocks

EV / EBITDA
−7.9×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
35.7%

Higher than 90% of US stocks

Return on assets
−57.2%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Avalyn Pharma, Inc. (AVLN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Avalyn Pharma, Inc. has a market value of $1.2B and an enterprise value of $872.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$93.5M.

  • Diluted earnings per share, trailing twelve months: $−2.20.

  • Free cash flow in the twelve months to 30 June 2026: −$96.5M.

  • Shares outstanding: 44.3M.

  • Trailing P/E: −13.4×; forward P/E: −10.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Avalyn Pharma, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 23 Oct 2026

Data provided by Twelve Data

Peers

AVLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVLNAvalyn Pharma, Inc.$1.2B1
OMEROmeros Corp.$1.2B92
VSTMVerastem, Inc.$1.2B68
DRTSAlpha Tau Medical Ltd.$1.2B14
KARDKardigan, Inc.$1.2B0
SNDXSyndax Pharmaceuticals, Inc.$1.2B58
BCAXBicara Therapeutics, Inc.$1.2B54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Avalyn Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVLN news & analysis

Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile

GlobeNewsWire · 21 Sept 2026positive

Avalyn published Phase 1 data for AP02 highlighting its lung-targeted delivery of an established antifibrotic medicine and an encouraging safety profile. The results validate the company's approach of delivering the medicine directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability.

Why it matters — For AVLN watchers, this data supports the core thesis behind the company's pipeline by validating that its lung-targeted delivery can potentially improve tolerability of an established antifibrotic medicine.

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors

GlobeNewsWire · 16 Sept 2026positive

Avalyn Pharma announced the appointment of Robert (Bob) J. Meyer, MD, a pulmonary physician and former senior FDA leader, to its Board of Directors. Dr. Meyer previously served as Principal of Drug and Biologics Products at Greenleaf Health (now Eliquent Life Sciences).

Why it matters — Avalyn watchers would view this as adding significant regulatory and respiratory expertise to the board as the clinical-stage company advances its inhaled therapies for rare respiratory diseases.

Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

A transcript of Avalyn Pharma Inc.'s presentation at the Morgan Stanley 24th Annual Global Healthcare Conference was published. The item consists of the company's presentation transcript from the conference.

Why it matters — AVLN watchers would care because the presentation transcript offers direct insight into the company's messaging delivered to an investment conference audience.

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 8 Sept 2026neutral

Avalyn Pharma announced that its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 14, 2026, from 1:50-2:25 p.m. ET.

Why it matters — The fireside chat gives Avalyn management an opportunity to present the company and its inhaled therapies to investors and industry attendees at a major healthcare conference.

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

GlobeNewsWire · 8 Sept 2026positive

Avalyn Pharma presented new data at the ERS Congress 2026. In silico modeling predicts robust AP01 aerosol distribution in healthy and fibrotic lungs, even in severe disease, and patient survey findings suggest that clear communication, transparent benefit-risk discussions, and reduced logistical burden may support engagement in future pulmonary fibrosis clinical studies.

Why it matters — The data support the lung distribution and patient-centered design of AP01's clinical program, which is relevant for Avalyn's lead inhaled therapy candidate in pulmonary fibrosis.

FAQ

Frequently asked questions about AVLN stock

What is the AVLN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Avalyn Pharma, Inc. have a median 12-month price target of $60, with estimates ranging from $52 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVLN stock a buy right now?

Of the 5 analysts covering Avalyn Pharma, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Avalyn Pharma, Inc. 1 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVLN?

As at 22 Oct 2026, Avalyn Pharma, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (41 of 100).

Will AVLN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +120.2% from the last close, and Ticker Nerd's factor model ranks Avalyn Pharma, Inc. 1 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVLN stock forecast for 2030?

No analyst covering Avalyn Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $52 to $80 over the next 12 months.

What does Avalyn Pharma, Inc. do?

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled medicines for serious rare respiratory diseases.

What is the latest news on AVLN?

The most recent item we track (GlobeNewsWire, 21 Sept 2026): "Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile". Avalyn published Phase 1 data for AP02 highlighting its lung-targeted delivery of an established antifibrotic medicine and an encouraging safety profile. The results validate the company's approach of delivering the medicine directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability.

Company

About Avalyn Pharma, Inc.

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled medicines for serious rare respiratory diseases. Its current programs center on pulmonary fibrosis and other interstitial lung diseases, using formulations designed to deliver established antifibrotic medicines directly to the lungs. The company’s pipeline includes AP01 and AP02, inhaled versions of pirfenidone and nintedanib for conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, as well as AP03, a combination approach intended to provide dual antifibrotic activity. Avalyn Pharma Inc. operates in the biotechnology segment of the healthcare market and is oriented toward targeted therapies for unmet needs in rare lung disease.

CEO Ms. Lyn Baranowski · 55 employees · United States · https://www.avalynpharma.com